CEO Appointment:

Neogenix Oncology Inc., of Great Neck, N.Y., appointed Philip Arlen CEO. Arlen, who initially had joined the firm in July 2008 as president and chief medical officer, spent 11 years at the National Cancer Institute before joining Neogenix.

In other A&A News:

Catalyst Biosciences Inc., of South San Francisco, appointed William J. Dawson chief financial officer.

Cytos Biotechnology Ltd., of Zurich, Switzerland, named Thomas Hecht chairman of the board.

IBio Inc., of Newark, Del., appointed Philip K. Russell to its board and named Vidadi Yusibov chief scientific officer.

Kinex Pharmaceuticals, of Buffalo, N.Y., named Charles E. Lannon vice chairman of the board.

Pacific Biosciences, of Menlo Park, Calif., named Susan K. Barnes chief financial officer.

Vermillion Inc., of Fremont, Calif., appointed Carl Severinghaus to its board.

Regenesis Biomedical Inc., of Scottsdale, Ariz., appointed Peter Sheehan to its board.